Gilead Sciences, Inc. (GILD)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for GILD is $159.20, 1.9% above the last close of $156.19 on Oct 16, 2026; targets range from $126.28 to $178.77. Rating consensus: Buy.
Snapshot
- P/E—
- P/E vs sector—
- P/E vs own—
- Target upside+1.9%
- ConsensusBuy
- Market cap$194B
- FCF yield+6.8%
- Insiders-$15.88M
- Earnings in13d
- News0.00
Why it moved
Gilead Sciences, Inc. (GILD) fell 0.7% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.
0 stories on the day (30-day average 0.8).
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $156.19 · +35.8% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendbullish
- Sector▲ +16.0%
- MAs20▲ 50▲ 100▲ 200▲
- Above MAs4 of 4 above
- MA20×50↓ in ~19d
- RSI64
- Support-2.1%
- Resistance—
- Off 52w high-0.7%
- Off ATH-0.7%
- 52w range$156.19
- Bollingerupper half
- MACD0.68
- ATR+2.4%
- Volume1.4x
Analyst price targets
20 firms with a target in the last 12 months · last close $156.19 · as of Oct 16, 2026
Strong buy 6 · Buy 16 · Hold 5 · Sell 0 · Strong sell 1
Revenue and free cash flow
Q2 FY2026: Revenue +10.2% year over year, free cash flow 47.3% of revenue, operating margin -133.2%.
| Q2 FY2026 | Jun 30, 2026 | $7.8B | -8.45 | $3.69B | 79.8% | -133.2% | -134.5% |
| Q1 FY2026 | Mar 31, 2026 | $6.96B | 1.61 | $2.43B | 79.2% | 37.2% | 29.0% |
| Q4 FY2025 | Dec 31, 2025 | $7.92B | 1.74 | $3.12B | 79.5% | 37.7% | 27.5% |
| Q3 FY2025 | Sep 30, 2025 | $7.77B | 2.43 | $3.96B | 79.8% | 42.8% | 39.3% |
| Q2 FY2025 | Jun 30, 2025 | $7.08B | 1.56 | $720M | 78.8% | 34.9% | 27.7% |
| Q1 FY2025 | Mar 31, 2025 | $6.67B | 1.04 | $1.65B | 76.9% | 33.6% | 19.7% |
| Q4 FY2024 | Dec 31, 2024 | $7.57B | 1.42 | $2.83B | 79.1% | 32.4% | 23.6% |
| Q3 FY2024 | Sep 30, 2024 | $7.54B | 1.00 | $4.17B | 79.1% | 11.8% | 16.6% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $255.56 | +0.9% | -8.2% | +8.8% | 38.7 | $616B | |
| 2 |  | $285.42 | +0.7% | 0.0% | -1.4% | 80.4 | $504B | |
| 3 |  | $145.95 | +0.5% | -6.2% | +7.7% | 116.8 | $360B | |
| 4 |  | $432.49 | -0.4% | -2.6% | -7.5% | 26.9 | $234B | |
| 5 | | $156.19 | -0.7% | -0.7% | +1.9% | — | $194B | |
| 6 |  | $29.58 | +0.5% | 0.0% | -7.1% | 39.1 | $169B | |
| 7 |  | $59.75 | -1.4% | -11.3% | +9.4% | 13.2 | $122B | |
| 8 |  | $232.65 | -1.1% | -1.1% | +2.7% | 41.2 | $34.37B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.